MRSN

Mersana Therapeutics
MRSN

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$48.61M
EV
$-57.36M
Shares Outstanding
124.63M
Beta
1.66

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$4.71
P/E 2025E
-
P/Revenue 2025E
1.76x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Mersana Therapeutics, Inc.

gainify
MRSN

Mersana Therapeutics, Inc.

MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has ...

Sector

Healthcare

Industry

Biotechnology

CEO

Huber, Martin

Employees

102

IPO Date

2017-06-28

Headquarters

840 Memorial Drive, Cambridge, Massachusetts, 02139, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved